Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: Application to a clinical pharmacokinetic study

Biomedical Chromatography

Volumn 22, Issue 6, 2008, Pages 645-653

  Bharathi, D Vijaya ^a,b   Naidu, A ^a   Jagadeesh, B ^b   Maha Laxmi, K N K ^b   Naga Laxmi, P Revathi ^b   Reddy, Pandu Ranga ^b   Mullangi, Ramesh ^b  

^a JNTUH COLLEGE OF ENGINEERING   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Human plasma; LC MS MS; Pharmacokinetics; Validation; Zafirlukast

Indexed keywords

PHARMACOKINETICS; PLASMA (HUMAN);

CLINICAL PHARMACOKINETICS; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; LEUKOTRIEN; PHARMACOKINETIC STUDIES; VALDECOXIB; VALIDATION; ZAFIRLUKAST;

ELECTROSPRAY IONIZATION;

ACETIC ACID ETHYL ESTER; ACETONITRILE; AMMONIUM ACETATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; VALDECOXIB; ZAFIRLUKAST;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 46949106905     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.983     Document Type: Article

References (10)

1. Bui KH, Kennedy CM, Azumaya CT and Birmingham BK. Determination of zafirlukast, a selective leukotriene antagonist, human plasma by normal-phase high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B 1997; 696: 131-136.
2. Dams R, Huestis MA, Lambert WE and Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Journal of the American Society for Mass Spectrometry 2003; 14: 1290-1294.
3. Dekhuilzen PN and Koopmans PP. Pharmacokinetic profile of zafirlukast. Clinical Pharmacokinetics 2002; 41: 105-114.
4. Ficarra R, Ficarra P, Tommasini S, Melardi S, Calabro ML, Furlanetto S and Semreen M. Validation of a LC method for the analysis of zafirlukast in pharmaceutical formulation. Journal of Pharmaceutical and Biomedical Analysis 2000; 23: 169-174.
5. Fischer JD, Song MH, Suttle AB, Heizer WD, Burns CB, Vargo DL and Brouwer KL. Comparison of zafirlukast (Accolate) absorption after oral and colonic administration in humans. Pharmaceutical Research 2000; 17: 154-159.
6. Hubert Ph, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, Bervoas-Martin S, Chevalier P, Grandjean D, Lagorce P, Lallier M, Laparra MC, Laurentie M and Nivet JC. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis Washington conférence to the laboratory. Analytica Chimica Acta 1999; 391: 135-148.
7. Radhakrishna T, Satyanarayana J and Satyanarayana A. Determination of zafirlukast by stability indicating LC and derivative spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 2002; 30: 695-703.
8. Suslu I and Altinoz S. A reversed-phase high-performance liquid chromatographic method for the determination of zafirlukast in pharmaceutical formulations and human plasma. Journal of AOAC International 2006; 89: 1557-1564.
9. Suslu I, Demircan S, Altinoz S and Kir S. Optimisation, validation and application of a capillary electrophoretic method for the determination of zafirlukast in pharmaceutical formulations. Journal of Pharmaceutical and Biomedical Analysis 2007; 44: 16-22.
10. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001. Available at: www/fda.gov/cder/guidance/ index.htm